Tech Company Financing Transactions
Xenogen Funding Round
Xenogen closed a $22 million investment round on 7/10/2003. Investors included Abingworth.
Transaction Overview
Company Name
Announced On
7/10/2003
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Undisclosed
Investors
Abingworth (Lead Investor) (Michael Bigham)
Proceeds Purpose
Capital to be Used for the Continued Commercialization of Xenogen's Unique Real-Time In Vivo Imaging Technology.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
860 Atlantic Avenue
Alameda, CA 94501
USA
Alameda, CA 94501
USA
Phone
Website
Email Address
Not Recorded
Overview
Xenogen is a leading biotechnology company and developer of in vivo biophotonic technology, which allows real-time, non-invasive exploration of genes, proteins, pathogens, and tumor cells in living animals.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
David Carter
Browse more venture capital transactions:
Prev: 7/10/2003: Carefx venture capital transaction
Next: 7/11/2003: ImmunGene venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on tech company VC transactions. VC investment data records on this site come from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs